Investor Presentation H1 2023

57 Investor presentation First six months of 2023 Phase 3 trial programme, COMBINE, has been initiated with IcoSema IcoSema characteristics IcoSema is a fixed dose combination of insulin icodec and semaglutide • Simple and convenient once-weekly injection کی COMBINE 1 Post-basal insulin Focused phase 3 trial programme • • • Initiated in Q2 2022 1290 patients* previously on basal-insulin 52-week vs. insulin icodec • Prim. endpoint: HbA₁, superiority • Sec. endpoint: Weight and hypo superiority COMBINE 2 Post-GLP-1 • Phase 3a programme with IcoSema . Aims to confirm efficacy and safety across three global trials Expected completion during 2024 COMBINE 3 Basal insulin intensification *Patients with Type 2 Diabetes Mellitus . • Initiated in Q2 2022 680 patients* previously on GLP-1 RA 52-week vs. semaglutide 1.0mg Primary endpoint: HbA1c superiority • • • • Initiated in Q4 2021 680 patients* previously on basal insulin 52-week vs. insulin glargine + insulin aspart ⚫ Prim. endpoint: HbA₁, non-inferiority • Sec. endpoint: Weight and hypo superiority 2021 2022 2023 2024 Novo NordiskⓇ

View entire presentation